You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 144 No. 4, April 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Invited Critique
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Aging/ Geriatrics
 •Surgical Oncology
 •Diagnosis
 •Prognosis/ Outcomes
 •Liver/ Biliary Tract/ Pancreatic Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Treatment Strategy for Intraductal Papillary Mucinous Neoplasm of the Pancreas Based on Malignant Predictive Factors—Invited Critique

David B. Adams, MD

Arch Surg. 2009;144(4):349-350.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The Nobel physicist Sir Ernest Rutherford said, "all science is either physics or stamp collecting."1 It is difficult to realize that surgical science is frequently closer to stamp collecting than to physics. We examine information from our collection of patients and try to define disease on the basis of the data at hand. Much is missing from the record, and we overcome this with a variety of statistical tools and insightful leaps of imagination. The question goes begging, "What do we know about what we do not know?" With IPMN we constantly need to remind ourselves that there is much we do not know. The conventional wisdom is that branch-duct IPMNs are less aggressive than main-duct IPMNs, malignancy is more common in older patients, malignancy is found in about 70% of resected main-duct IPMNs, recurrence is rare after resection of noninvasive IPMNs, and recurrence occurs in . . . [Full Text of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Treatment Strategy for Intraductal Papillary Mucinous Neoplasm of the Pancreas Based on Malignant Predictive Factors
Seiko Hirono, Masaji Tani, Manabu Kawai, Shinomi Ina, Ryohei Nishioka, Motoki Miyazawa, Yoichi Fujita, Kazuhisa Uchiyama, and Hiroki Yamaue
Arch Surg. 2009;144(4):345-349.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.